JAN 1 7 2002

TRANSMITTAL LETTER

Case No. 10466/118

Group Art Unit

Serial No. 09/909,204 Filing Date July 18, 2001	Examiner To be assigned	Group Art Unit 1645
Inventor(s)		
Ashkenazi et al.	THE THE	SAME
Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUC	CLEIC ACIDS ENCODING THE	SAIVIE
SECRETED AND TRANSMEMBRANE FORTE		

Ŀ	TO THE COMMISSIONER FOR PATENTS										
	Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or										
		Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously									
		A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.									
		Petition for amonth extension of time.									
	\boxtimes	No additional fee	e is required								
		The fee has been calculated as shown below: Other Than									
•						_	Small E	ntity	۱ ا	Small E	ntity
,		Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'l Fee	or	Rate	Add'I Fee
	1 1	Amendment	Minus				x \$9=		-	x \$18=	
	Total		Minus			_	x 42=		-	x \$84=	
	Indep.	esentation of Mul		laim	<u> </u>		+ \$140=	 	-	+ \$280 = Total	\$
	FIRST FI	esentation or	· · · · · · · · · · · · · · · · · · ·				Total add'l fee	\$]	add'l fee	
Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed. A check in the amount of \$ to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. Respectfully submitted,										37 CFR § n or credit	
Gregory M. Zinkl, Ph.D. Registration No. 48,492 Agent for Applicant											
	P.O. CHI (312	IKS HOFER GILSO BOX 10395 CAGO, ILLINOIS 6 2) 321-4200	0610		10 to	netal C	ervice as				
I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 398314070US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on Date: Date: Signature:											



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/909,204

07/18/2001

Avi Ashkenazi

P1618P2C81

CONFIRMATION NO. 1632

FORMALITIES LETTER

OC000000007119622*

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599

Date Mailed: 11/26/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE